National Comprehensive Cancer Network

About NCCN

NCCN Flash Updates™: NCCN Guidelines® and NCCN Compendium® Updated

has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)  and NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Non-Hodgkin’s Lymphomas. These NCCN Guidelines® are currently available as Version 3.2016. 

  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    • CLL with del(17p)/TP53 mutation (CSLL-D 3 of 7)
      • For relapsed/refractory therapy, venetoclax was added as an option with a category 2A designation.
    • A new page titled, "Venetoclax: Recommended TLS Prophylaxis and Monitoring Based on Tumor Burden" was added. (CSLL-F)

*For your reference, the previous update (Version 2.2016) to the NCCN Guidelines for Non-Hodgkin’s Lymphomas, published on February 17, 2016, is available at the following link:

For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, NCCN Compendium®, and the NCCN Chemotherapy Order Templates (NCCN Templates®), please visit

To access the NCCN Biomarkers Compendium®, please visit

To view the NCCN Guidelines for Patients®, please visit

Free NCCN Guidelines apps iPhone, iPad, and Android devices are now available! Visit

 About NCCN Flash Updates™ 

NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium, and other NCCN Content. 

Subscribe to NCCN Flash Updates™ 

National Comprehensive Cancer Network® (NCCN®)

275 Commerce Drive, Suite 300

Fort Washington, PA 19034

Telephone: +1 215.690.0300 Fax: +1 215.690.0280 

Access information on permissions and licensing of NCCN Content  

© 2016 National Comprehensive Cancer Network. All Rights Reserved.